Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin’s lymphoma patients: a single centre study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
http://www.nature.com/articles/1702378.pdf
Reference41 articles.
1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma New Engl J Med 1995 333: 1540–1545
2. Weaver C, Schwartzberg L, Zhen B et al. High dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin’s lymphoma: results of outpatient treatment in community cancer centers Bone Marrow Transplant 1997 20: 753–760
3. Mills W, Chopra A, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non Hodgkin’s lymphoma J Clin Oncol 1995 13: 588–595
4. Haioun C, Lepage E, Gisselbrecht C et al. High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin’s lymphoma Ann Oncol 1998 9: (Suppl.1) 5S-8S
5. Perry A, Goldstone A . High dose therapy for diffuse large-cell lymphoma in first remission Ann Oncol 1998 9: (Suppl.1) 9S-14S
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of plerixafor (mozobil) on hospital efficiency: A single center experience;Journal of Clinical Apheresis;2017-04-28
2. Hematopoietic progenitor cell mobilization for autologous transplantation – a literature review;Revista Brasileira de Hematologia e Hemoterapia;2016-01
3. Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization;Biology of Blood and Marrow Transplantation;2013-01
4. Experience with Apheresis Procedures After Plerixafor Mobilisation;Novel Developments in Stem Cell Mobilization;2011-12-20
5. Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkinʼs Lymphoma;PharmacoEconomics;2009
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3